醫藥股普遍上升 藥明巨諾升18% 翰森及來凱升7%
恆指午後曾跌逾221點,低見17,303,現報17,351,跌173點或1%,總成交額792億元。
醫藥板塊普遍逆市造好,其中藥明巨諾-B(02126.HK)承接上日升勢,高見3.22元,現報3.2元 ,升18.5%,成交股數倍增至365萬股。
半新股來凱醫藥-B(02105.HK)扭轉上日跌勢,高見20.9元,現報20.2元,回升7%。維亞生物(01873.HK)升逾5%報1.23元,重上10天及20天線。
藍籌石藥(01093.HK)及翰森(03692.HK)均重上10天線,現報7.17元及15.68元,升4.2%及6.8%;中生(01177.HK)及國藥(01099.HK)升2.4%及2%,報3.84元及19.82元,均重上10天線。
康方生物(09926.HK)高見50.8元,創近十個月高,現報50.1元,升4.7%;君實(01877.HK)升4.4%報22.6元,重上10天及20天線。先聲藥業(02096.HK)升逾2%報7.52元,重上10天線。上海醫藥(02607.HK)升1.8%報11.62元。
康希諾(06185.HK)重上10天及20天線,最高見27.8元,現報27.4元,升3.4%;其A股(688185.SH)收市升3.9%。
百心安-B(02185.HK)下跌,低見3.99元,現報4.05元,跌4.3%。昨天創上市新低的開拓藥業-B(09939.HK),再跌3.5%報2.23元。騰盛博藥-B(02137.HK)跌逾2%報3.01元。艾美疫苗(06660.HK)跌逾2%報8.94元。
藍籌藥明生物(02269.HK)跌0.8%,現報45.7元;掛牌第八天的藥明合聯(02268.HK)跌0.5%,報29.05元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.